Apellis Pharmaceuticals Inc (APLS)
27.75
+0.26
(+0.95%)
USD |
NASDAQ |
Nov 21, 16:00
27.73
-0.02
(-0.07%)
After-Hours: 20:00
Apellis Pharmaceuticals Total Assets (Quarterly): 901.87M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 901.87M |
June 30, 2024 | 904.48M |
March 31, 2024 | 831.93M |
December 31, 2023 | 788.73M |
September 30, 2023 | 818.22M |
June 30, 2023 | 915.58M |
March 31, 2023 | 978.87M |
December 31, 2022 | 760.22M |
September 30, 2022 | 872.89M |
June 30, 2022 | 1.002B |
March 31, 2022 | 1.146B |
December 31, 2021 | 881.76M |
September 30, 2021 | 525.69M |
June 30, 2021 | 699.91M |
March 31, 2021 | 810.13M |
December 31, 2020 | 960.57M |
September 30, 2020 | 768.33M |
June 30, 2020 | 870.11M |
Date | Value |
---|---|
March 31, 2020 | 688.94M |
December 31, 2019 | 389.24M |
September 30, 2019 | 466.36M |
June 30, 2019 | 316.70M |
March 31, 2019 | 318.35M |
December 31, 2018 | 203.53M |
September 30, 2018 | 239.15M |
June 30, 2018 | 266.82M |
March 31, 2018 | 163.20M |
December 31, 2017 | 182.13M |
September 30, 2017 | 19.14M |
June 30, 2017 | 56.69M |
December 31, 2016 | 27.43M |
December 31, 2015 | 38.18M |
September 30, 2015 | 13.74M |
June 30, 2015 | 16.82M |
December 31, 2014 | 14.31M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
389.24M
Minimum
Dec 2019
1.146B
Maximum
Mar 2022
825.79M
Average
851.02M
Median
Total Assets (Quarterly) Benchmarks
Biomarin Pharmaceutical Inc | 6.851B |
Ionis Pharmaceuticals Inc | 3.081B |
EyePoint Pharmaceuticals Inc | 300.92M |
Cassava Sciences Inc | 223.75M |
Macrogenics Inc | 264.49M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 664.74M |
Shareholders Equity (Quarterly) | 237.12M |
Debt to Equity Ratio | 1.907 |
Current Ratio | 4.36 |
Net Debt Paydown Yield | -2.04% |